Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 181

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 181
---

    )

    Accounts payable, accrued expenses and other liabilities

    (744
    )

    9,369

    Right-of-use assets and lease liabilities, net

    184

    (186
    )

    Net cash used in operating activities

    (69,774
    )

    (50,139
    )

    Cash flows from investing activities:

    Purchases of marketable securities

    (263,624
    )

    (143,835
    )

    Maturities of marketable securities

    165,885

    —

    Purchases of property and equipment

    (664
    )

    (770
    )

    Net cash used in investing activities

    (98,403
    )

    (144,605
    )

    Cash flows from financing activities:

    Proceeds from issuances of common stock under benefit plans

    2,557

    1,537

    Proceeds from issuance of common stock and pre-funded warrants from Private Placement

    200,000

    —

    Payments of issuance costs for common stock and pre-funded warrants from Private Placement

    (420
    )

    —

    Net cash provided by financing activities

    202,137

    1,537

    Net cash increase (decrease) for the period

    33,960

    (193,207
    )

    Cash, cash equivalents and restricted cash at beginning of the period

    59,006

    252,213

    Cash, cash equivalents and restricted cash at end of the period
     
    $
    92,966

    $
    59,006

    Reconciliation of cash, cash equivalents and restricted cash to the    balance sheet

    Cash and cash equivalents
     
    $
    91,966

    $
    58,006

    Restricted cash

    1,000

    1,000

    Total cash, cash equivalents and restricted cash
     
    $
    92,966

    $
    59,006

    Supplemental disclosure of cash flow information:

    Right-of-use assets obtained in exchange for lease liabilities
     
    $
    —

    $
    4,405

    Non-cash investing and financing activities:

    Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
     
    $
    —

    $
    125

    Vesting of